The cardiac enigma: Current conundrums in heart failure research

Michael S Kapiloff, Craig A. Emter

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient's symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.

Original languageEnglish (US)
Article number72
JournalF1000Research
Volume5
DOIs
StatePublished - 2016

Fingerprint

Heart Failure
Research
Translational Medical Research
Proxy
Treatment Failure
Population
Comorbidity
Heart Diseases
Therapeutics
Animals
Aging of materials
Survival
Health

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

The cardiac enigma : Current conundrums in heart failure research. / Kapiloff, Michael S; Emter, Craig A.

In: F1000Research, Vol. 5, 72, 2016.

Research output: Contribution to journalReview article

Kapiloff, Michael S ; Emter, Craig A. / The cardiac enigma : Current conundrums in heart failure research. In: F1000Research. 2016 ; Vol. 5.
@article{b00e0eecae394d95a9b0993f91cdfdbe,
title = "The cardiac enigma: Current conundrums in heart failure research",
abstract = "The prevalence of heart failure is expected to increase almost 50{\%} in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient's symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.",
author = "Kapiloff, {Michael S} and Emter, {Craig A.}",
year = "2016",
doi = "10.12688/f1000research.7278.1",
language = "English (US)",
volume = "5",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - The cardiac enigma

T2 - Current conundrums in heart failure research

AU - Kapiloff, Michael S

AU - Emter, Craig A.

PY - 2016

Y1 - 2016

N2 - The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient's symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.

AB - The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient's symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.

UR - http://www.scopus.com/inward/record.url?scp=84970979582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970979582&partnerID=8YFLogxK

U2 - 10.12688/f1000research.7278.1

DO - 10.12688/f1000research.7278.1

M3 - Review article

AN - SCOPUS:84970979582

VL - 5

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 72

ER -